Mr. Soriot isn’t expected to leave immediately, but the company reportedly hired headhunters to draw up a list of potential internal candidates. The Times reports that potential candidates could include AstraZeneca’s senior executives Mene Pangalos and Ruud Dobber.
The news comes after the drugmaker suffered a setback with the failure of a big lung cancer trial in November.
Mr. Soriot had promised to achieve at least $40 billion in sales by 2023, and the cancer drug setback pushes that goal further out of reach.
More articles on pharmacy:
Florida adds CVS, Walgreens to opioid lawsuit
Pfizer to hike price of 41 drugs in January
Bristol-Myers Squibb to lay off 69 employees in Florida
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
